Timothy Johnson, MD
Ophthalmology · Tuscaloosa, ALNPI 1386965622
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Biotissue Holdings Inc. at 43.4% of the total. 2025 is the largest year on record at $5,389, 3.5 times the $1,518 reported in 2019. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $88.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$6K
- Alcon$4K
- Microsurgical Technology, Inc.$700
- Bausch & Lomb Americas Inc.$688
- AbbVie$675
- Iridex Corporation$486
- plus $2K from 18 others
What the payments were for
- Consulting fees$3,40023%
- Travel & lodging$2,05414%
- Food & beverage$8,62558%
- Gifts$7005%
- Entertainment$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 19 | $6,469 |
| Alcon | 68 | $4,104 |
| Microsurgical Technology, Inc. | 1 | $700 |
| Bausch & Lomb Americas Inc. | 9 | $688 |
| AbbVie(2 entities) | 30 | $675 |
| Iridex Corporation | 4 | $486 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $396 |
| Ocular Therapeutix, Inc. | 5 | $235 |
| Oyster Point Pharma, Inc. | 1 | $133 |
| Glaukos Corporation | 1 | $125 |
| Optos, Inc. | 3 | $120 |
| Sun Pharmaceutical Industries Inc. | 1 | $119 |
| Nova Eye, Inc. | 1 | $92 |
| Dompe US, Inc. | 1 | $87 |
| Sight Sciences, Inc. | 1 | $82 |
| Astellas Pharma US Inc | 1 | $76 |
| Omeros Corporation | 4 | $65 |
| Ivantis, Inc | 1 | $51 |
| Rayner Intraocular Lenses Limited | 3 | $50 |
| Derma Sciences, Inc. | 1 | $44 |
| Tarsus Pharmaceuticals, Inc. | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$3,522
- Clareon$672
- Hydrus Microstent$382
- ARGOS$354
- AcrySof IQ PanOptix$332
- enVista MX60 IOL$259
- AcrySof IQ VIVITY IOL$251
- Clareon PanOptix Pro$250
- ReSTOR$151
- DEXTENZA$149
- STELLARIS$144
- TYRVAYA$133
- Unity$131
- Tecnis Simplicity$129
- AcrySof IQ VIVITY$126
- PanOptix$125
- KXL System$125
- Photrexa$125
- Centurion$121
- CEQUA$119
How this compares
$14,898 in reported general payments places this provider in the 95th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 37 | $21,077 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $15,811 |
| Latanoprost | 624 | $11,671 |
| Prednisolone Acetate | 285 | $9,182 |
| Alphagan PBrimonidine Tartrate | 27 | $7,423 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $6,696 |
| Travoprost | 25 | $6,523 |
| Ketorolac Tromethamine | 242 | $4,403 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 109 | $4,334 |
| Ofloxacin | 237 | $3,067 |
| Brimonidine Tartrate | 140 | $2,914 |
| Timolol Maleate | 166 | $2,514 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 164 | $2,466 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 76 | $1,192 |
| Dorzolamide Hcl | 23 | $644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $675 | $44,31092 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Tuscaloosa
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
- Sebastian HeersinkDothan$33K
- John ParkerVestavia$19K
- Lindsay RhodesBirmingham$18K
- James LewisBirmingham$15K
- In ShinMontgomery$12K
- Harsha SenDothan$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.